OPB 51602

Drug Profile

OPB 51602

Alternative Names: OPB-51602

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Otsuka Pharmaceutical
  • Class Antineoplastics
  • Mechanism of Action STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Chronic myeloid leukaemia; Multiple myeloma; Nasopharyngeal cancer; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 18 Jun 2015 National University Hospital in collaboration with Otsuka and Shin Nippon terminates a phase I trial in Nasopharyngeal cancer (Late-stage disease) in Singapore (NCT02058017)
  • 01 Apr 2014 Otsuka Pharmaceutical completes a phase I trial in Multiple myeloma, Non-Hodgkin lymphoma, Acute myeloid leukaemia, Acute lymphoid leukaemia, Chronic myeloid leukaemia (Second-line therapy or greater) in Japan (NCT01344876)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top